title: Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients.
abstract: Background:Published papers reported contradictory results about the correlation between bevacizumab effectiveness and primary tumor location of metastatic colorectal cancer (mCRC).Methods:740 mCRC patients treated with chemotherapy (CT group) and 244 patients treated with bevacizumab plus chemotherapy as first-line setting (CT + B group) were included. Propensity score analyses were used for patients' stratification and matching. Kaplan-Meier curves with log-rank tests were used to detect different overall survival (OS).Results:Patients in CT + B group had similar OS comparing with CT group only when the primary tumor located at right-side colon (20.2 for CT + B versus 19.7 months for CT group,p= 0.269). For left-side colon and rectal cancer patients, significantly longer OS were observed in CT + B than CT group.Conclusion:Our data suggested only patients with left-side colon or rectal cancer could get survival benefit from the addition of bevacizumab to first-line chemotherapy.
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Wen-Zhuo
authors.initials: WZ
authors.lastname: He
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Fang-Xin
authors.initials: FX
authors.lastname: Liao
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Chang
authors.initials: C
authors.lastname: Jiang
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Peng-Fei
authors.initials: PF
authors.lastname: Kong
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Chen-Xi
authors.initials: CX
authors.lastname: Yin
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Yang
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Hui-Juan
authors.initials: HJ
authors.lastname: Qiu
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Bei
authors.initials: B
authors.lastname: Zhang
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, P. R. China.
authors.forename: Liang-Ping
authors.initials: LP
authors.lastname: Xia
keywords: Colorectal cancer; and location.; bevacizumab; metastasis; prognosis